Latest Genzyme Stories

NOVATO, Calif., March 1, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Dan Maher, Senior Vice President of Product Development of BioMarin, will present a company update at the Cowen Health Care Conference in Boston on Tuesday, March 8, 2011 at 8:00 a.m. ET. Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com. A replay of the call will be archived on the site for...

NOVATO, Calif., Feb. 22, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Joshua Grass, Vice President of Corporate and Business Development of BioMarin, will present a company update at the Citi Global Healthcare Conference in New York City on Tuesday, March 1, 2011 at 8:00 a.m. ET. Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com. A replay of the call will be...

NOVATO, Calif., Feb. 17, 2011 /PRNewswire/ -- Financial Highlights ($ in millions, except per share data, unaudited) Item FY 2010 FY 2009 Comparison Total BioMarin Revenue $376.3 15.9% increase Total Net Product Revenue $369.7 17.1% increase Naglazyme Net Product Revenue $192.7 14.2% increase Aldurazyme...

PARIS and CAMBRIDGE, Mass., Feb. 16, 2011 /PRNewswire/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Genzyme Corporation (Nasdaq: GENZ) announced today that they have entered into a definitive agreement under which sanofi-aventis is to acquire Genzyme for $74.00 per share in cash, or approximately $20.1 billion(1). In addition to the cash payment, each Genzyme shareholder will receive one Contingent Value Right (CVR) for each share they own, entitling the holder to receive additional...

MISSISSAUGA, Ontario, Feb. 10, 2011 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that its subsidiary, Biovail Laboratories International SRL (BLS), has acquired the Canadian rights to Cholestagel® (colesevelam), an oral bile acid sequestrant for hypercholesterolemia, from Genzyme Corporation ("Genzyme"). Genzyme will receive from BLS a $2 million upfront payment, to be followed by subsequent additional milestone payments totaling up...

PARIS, Feb. 9, 2011 /PRNewswire/ -- Change on Q4 2010 a Change at ------- reported constant exchange basis rates ----- --------- Net sales EUR7,395m +0.5% -5.9% Business net income(1) EUR1,838m -0.3% -9.7%...

SOUTH PLAINFIELD, N.J., Jan. 25, 2011 /PRNewswire/ -- Prolong Pharmaceuticals, which in October secured a $30 million funding commitment from a private investment group, today announced the signing of a long term lease on a manufacturing facility in South Plainfield, New Jersey and the formal addition of Dr. Hemant Misra to the Prolong Executive Management team as Vice President, Manufacturing and Facilities Operations. The manufacturing facility has been used by Prolong since early 2010,...

NOVATO, Calif., Jan. 24, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, February 17, at 5:00 p.m. ET to discuss fourth quarter and full year 2010 financial results. U.S. / Canada Dial-in Number: 866.203.3206 International Dial-in Number: 617.213.8848 Participant Code: 90635895 Replay Dial-in Number: 888.286.8010...

CHICAGO, Jan. 17, 2011 /PRNewswire/ -- Zacks.com Analyst Blog features: Marathon Oil Corporation (NYSE: MRO), ExxonMobil (NYSE: XOM), Chevron Corp. (NYSE: CVX), ConocoPhillips (NYSE: COP) and Genzyme Corp. (Nasdaq: GENZ). (Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO) Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=4579 Here are highlights from Friday's Analyst Blog: Marathon Oil to Break in Two...

NOVATO, Calif., Jan. 11, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced the initiation of a Phase 1/2 trial for BMN 673, a poly ADP-ribose polymerase (PARP) inhibitor in development for the treatment of genetically-defined cancers. "PARP inihibtors have been validated to show survival benefits in cancer patients with tumors that have defects in DNA repair or in combination with DNA damaging agents, and BMN 673 appears to have superior potency,...